UroGen Pharma Ltd. (URGN) News
Track canonical SquawkNews coverage tagged to URGN, UroGen Pharma Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 20 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
URGN: Strong demand for Zusduri and advancing pipeline programs signal robust growth prospects
The discussion highlighted strong early demand for Zusduri, with significant room for physician adoption and growth, especially in community settings. Key pipeline milestones include UGN-103's upcoming data and approval,
NEWS | Sep 15, 2026, 02:50 PM UTC
L
URGN: Zusduri's rapid adoption and expanding pipeline signal strong growth and innovation ahead
RTGel technology underpins a growing portfolio targeting urologic cancers, with Zusduri's strong launch driven by physician demand and expanding adoption in community practices. Key milestones ahead include UGN-103 appro
NEWS | Sep 15, 2026, 02:07 PM UTC
L
URGN: Zusduri's demand-driven growth and expanding adoption set the stage for major pipeline milestones
RTGel technology underpins a strong launch for Zusduri, with revenue up 73% and growing physician adoption, especially in community practices. Pipeline progress includes UGN-103 and UGN-501, with key data and regulatory
EARNINGS | Sep 15, 2026, 01:48 PM UTC
L
URGN: Strong ZUSDURI launch, pipeline innovation, and market expansion drive long-term growth
The company is leveraging proprietary RTGel technology to lead in urothelial cancers, with ZUSDURI's strong launch and first-mover advantage in NMIBC driving growth. Next-generation products and pipeline expansion into h
EQUITY | Sep 09, 2026, 08:23 PM UTC
L
URGN: ZUSDURI's rapid adoption and pipeline innovation position the company for sustained growth
The event highlighted strong momentum for ZUSDURI, driven by first-mover advantage, expanding prescriber base, and robust payer coverage. Next-generation products and pipeline expansion, including UGN-103, UGN-104, and U
EQUITY | Sep 09, 2026, 08:10 PM UTC
L
UroGen Pharma announces inducement RSU grants under Nasdaq Rule 5635(c)(4)
UroGen Pharma Ltd. announced inducement restricted stock units (RSUs) to 19 new employees under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 12:07 PM UTC
L
UroGen Pharma announces inducement grants under Nasdaq Rule 5635(c)(4)
UroGen Pharma announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 12:00 PM UTC
L
UroGen Pharma to participate in September investor conferences
UroGen Pharma Ltd. said it will participate in investor conferences in September 2026.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
URGN - UroGen Pharma to Present at Upcoming Investor Conferences
URGN - UroGen Pharma to Present at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:00 PM UTC
L
URGN’s Urogen gains options for exclusive worldwide Oncology license
URGN’s intragel Therapeutics unit, Urogen, gains options for an exclusive worldwide license to develop up to three Oncology products, according to Hammerstone MarketTalk.
MNA | Aug 20, 2026, 11:07 AM UTC
M
Intragel Therapeutics signs Urogen collaboration; up to $7M equity
URGN-linked Intragel Therapeutics and Urogen Pharma enter strategic collaboration and investment agreements, with Intragel securing up to $7M equity for a Phase 2 tumocure study.
MNA | Aug 20, 2026, 11:06 AM UTC
L
UroGen enters strategic collaboration and investment deals with IntraGel
UroGen says it has signed strategic collaboration and investment agreements with IntraGel to access a biodegradable sustained-release gel platform and expand its oncology pipeline.
MNA | Aug 20, 2026, 11:00 AM UTC
L
URGN - UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
URGN - UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
EARNINGS | Aug 05, 2026, 12:00 PM UTC
L
URGN - UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
URGN - UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
EARNINGS | Jul 29, 2026, 12:00 PM UTC
L
URGN PT raised from $40 to $50, maintains Outperform @ OPCO
URGN PT raised from $40 to $50, maintains Outperform @ OPCO
EQUITY | Jul 16, 2026, 12:58 PM UTC
L
URGN - Reit Neutral, raise PT to $44 from $18 @ GSCO
URGN - Reit Neutral, raise PT to $44 from $18 @ GSCO
EQUITY | Jul 15, 2026, 09:26 PM UTC
L
URGN Urogen receives new U.S. patent allowance expected to provide Protection into July 2044 for zusduri™ and ugn-103 Urogen Pharma - U.S. p
URGN Urogen receives new U.S. patent allowance expected to provide Protection into July 2044 for zusduri™ and ugn-103 Urogen Pharma - U.S. patent expected to expire in July 2044 - Patent claims cover treatment of recurre
EQUITY | Jul 15, 2026, 12:04 PM UTC
L
Urogen Pharma Insider Sold Shares Worth $400,000, According to a Recent SEC Filing
() -- Mark Schoenberg, Chief Medical Officer, on July 09, 2026, sold 10,000 shares in Urogen Pharma (URGN) for $400,000. Following the Form 4 filing with the SEC, Schoenberg has control over a total of 119,763 ordinary s
REGULATION | Jul 10, 2026, 06:28 PM UTC
L
UroGen Pharma Gets FDA Clearance to Begin Phase 1 Trial of UGN-501
() -- UroGen Pharma (URGN) said Wednesday the US Food and Drug Administration cleared its investigational new drug application for UGN-501, allowing the company to begin a phase 1 trial in patients with non-muscle invasi
REGULATION | Jul 08, 2026, 12:23 PM UTC
L
UroGen Pharma announces FDA clearance for UGN-501 IND application
UroGen Pharma announced that the FDA cleared the company's investigational new drug application, or IND, for UGN-501, an investigational oncolytic virus. The IND clearance enables initiation of a planned Phase 1 clinical
REGULATION | Jul 08, 2026, 12:03 PM UTC